{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:09Z","timestamp":1791648429005,"version":"4.3.4"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.2169\/internalmedicine.6349-25","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T22:06:35Z","timestamp":1761775595000},"page":"1693-1698","source":"Crossref","is-referenced-by-count":3,"title":["Hyperacute Guillain-Barr\u00e9 Syndrome Reaching Clinical Nadir Within 16 Hours"],"prefix":"10.2169","volume":"65","author":[{"given":"Taiki","family":"Matsubayashi","sequence":"first","affiliation":[{"name":"Department of Neurology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Furuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Uchibori","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kyorin University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis. Neuroepidemiology 36: 123-133, 2011.","DOI":"10.1159\/000324710"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain-Barr\u00e9 syndrome. Expert Rev Clin Immunol 16: 1053-1064, 2020.","DOI":"10.1080\/1744666X.2021.1840355"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol 15: 671-683, 2019.","DOI":"10.1038\/s41582-019-0250-9"},{"key":"4","unstructured":"4. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barr\u00e9 syndrome. Brain 141: 2866-2877, 2018."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome. Eur J Neurol 30: 3646-3674, 2023.","DOI":"10.1111\/ene.16073"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson&apos;s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184, 1992.","DOI":"10.1136\/jnnp.55.3.181"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ<sub>1b<\/sub> IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barr\u00e9 syndrome: clinical and immunohistochemical studies. Neurology 43: 1911-1917, 1993.","DOI":"10.1212\/WNL.43.10.1911"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Uchibori A, Gyohda A, Chiba A. Ca<sup>2+<\/sup>-dependent anti-GQ<sub>1<\/sub>b antibody in GQ<sub>1<\/sub>b-seronegative Fisher syndrome and related disorders. J Neuroimmunol 298: 172-177, 2016.","DOI":"10.1016\/j.jneuroim.2016.07.021"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Schwerer B. Antibodies against gangliosides: a link between preceding infection and immunopathogenesis of Guillain-Barr\u00e9 syndrome. Microbes Infect 4: 373-384, 2002.","DOI":"10.1016\/S1286-4579(02)01550-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ho TW, Mishu B, Li CY, et al. Guillain-Barr\u00e9 syndrome in northern China relationship to <i>Campylobacter jejuni<\/i> infection and anti-glycolipid antibodies. Brain 118: 597-605, 1995.","DOI":"10.1093\/brain\/118.3.597"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Ann Neurol 44: 780-788, 1998.","DOI":"10.1002\/ana.410440512"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S. Optimizing the electrodiagnostic accuracy in Guillain-Barr\u00e9 syndrome subtypes: criteria sets and sparse linear discriminant analysis. Clin Neurophysiol 128: 1176-1183, 2017.","DOI":"10.1016\/j.clinph.2017.03.048"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Steiner I, Wirguin I, Blumen SC, et al.  &apos;Hyperacute&apos; Guillain-Barr\u00e9 syndrome. Eur Neurol 59: 88-90, 2008.","DOI":"10.1159\/000109575"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kenan G, Regev T, Kushnir M, et al. Reasons for delayed treatment initiation in Guillain-Barre syndrome. J Neurol Sci 434: 120179, 2022.","DOI":"10.1016\/j.jns.2022.120179"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Min YG, Hong YH, Rajabally YA, Sung JJ. Timing of intravenous immunoglobulin treatment and outcome in Guillain-Barr\u00e9 syndrome: is time nerve? Muscle Nerve 70: 1215-1222, 2024.","DOI":"10.1002\/mus.28271"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhu J, Zhang Y, Li R, et al. Anti-ganglioside antibodies in Guillain-Barre syndrome: a novel immunoblotting-panel assay. Front Neurol 12: 760889, 2021.","DOI":"10.3389\/fneur.2021.760889"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sejvar JJ, Kohl KS, Gidudu J, et al.; Brighton Collaboration GBS Working Group. Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29: 599-612, 2011.","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kuwabara S, Ogawara K, Mizobuchi K, et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barr\u00e9 syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry 68: 191-195, 2000.","DOI":"10.1136\/jnnp.68.2.191"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wong AH, Umapathi T, Nishimoto Y, Wang YZ, Chan YC, Yuki N. Cytoalbuminologic dissociation in Asian patients with Guillain-Barr\u00e9 and Miller Fisher syndromes. J Peripher Nerv Syst 20: 47-51, 2015.","DOI":"10.1111\/jns.12104"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. de Montaudouin M, Fleury O, Rouanet M, Renou P, Rouanet F, Sibon I. Hyperacute Guillain-Barr\u00e9 syndrome mimicking stroke: report of 3 cases: Guillain-Barr\u00e9 and stroke. Am J Emerg Med 32: 1152.e3-1152.e5, 2014.","DOI":"10.1016\/j.ajem.2014.02.019"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Vinay B, Sonia B, Bhadrinarayan V. Hyperacute onset of Guillain Barre syndrome in the immediate postpartum period following Caesarean section under spinal anaesthesia. Indian J Anaesth 59: 391-392, 2015.","DOI":"10.4103\/0019-5049.158782"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kommu S, Cirra V, Pesala SPR, Arepally S. Atypical Guillain-Barre syndrome with a sensory level and hyper-acute presentation: a case report. Cureus 15: e38262, 2023.","DOI":"10.7759\/cureus.38262"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barr\u00e9 syndrome. Ann Neurol 44: 202-208, 1998.","DOI":"10.1002\/ana.410440210"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barr\u00e9 syndromes. Neurology 61: 471-474, 2003.","DOI":"10.1212\/01.WNL.0000081231.08914.A1"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6349-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:37:32Z","timestamp":1781926652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6349-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6349-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"6349-25"}}